These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36654091)

  • 41. Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett BL; Packer M; Zannad F; Anand IS; Pieske B; Zhao Z; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Heart Assoc; 2021 Sep; 10(17):e022069. PubMed ID: 33998278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
    Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
    JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
    Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR
    Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sacubitril/valsartan: beyond natriuretic peptides.
    Singh JSS; Burrell LM; Cherif M; Squire IB; Clark AL; Lang CC
    Heart; 2017 Oct; 103(20):1569-1577. PubMed ID: 28689178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients.
    Valentim Goncalves A; Pereira-da-Silva T; Galrinho A; Rio P; Moura Branco L; Soares R; Ilhao Moreira R; Cruz Ferreira R
    Am J Cardiovasc Dis; 2020; 10(3):174-181. PubMed ID: 32923098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
    Burke RM; Lighthouse JK; Mickelsen DM; Small EM
    Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
    Martín-Garcia A; López-Fernández T; Mitroi C; Chaparro-Muñoz M; Moliner P; Martin-Garcia AC; Martinez-Monzonis A; Castro A; Lopez-Sendon JL; Sanchez PL
    ESC Heart Fail; 2020 Apr; 7(2):763-767. PubMed ID: 32022485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
    Pugliese NR; Fabiani I; Zywicki V; Mazzola M; D'Agostino A; Galeotti GG; Dini FL
    Curr Med Res Opin; 2019 May; 35(sup3):13-18. PubMed ID: 30895809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
    Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
    Zhang Y; Wu Y; Zhang K; Ke Z; Hu P; Jin D
    Coron Artery Dis; 2021 Aug; 32(5):427-431. PubMed ID: 32868662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients.
    Imamura T; Kinugawa K
    Ann Palliat Med; 2022 Sep; 11(9):2856-2861. PubMed ID: 36096739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review.
    Proudfoot C; Studer R; Rajput T; Jindal R; Agrawal R; Corda S; Senni M
    Int J Cardiol; 2021 May; 331():164-171. PubMed ID: 33545266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium.
    Primessnig U; Deißler PM; Wakula P; Tran KL; Hohendanner F; von Lewinski D; Blaschke F; Knosalla C; Falk V; Pieske B; Grubitzsch H; Heinzel FR
    Front Cardiovasc Med; 2022; 9():859014. PubMed ID: 35865376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure.
    Chen L; Yan KP; Liu XC; Wang W; Li C; Li M; Qiu CG
    Arch Pharm Res; 2018 Jan; 41(1):101-109. PubMed ID: 29124661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
    Korshunov VA; Quinn B; Faiyaz A; Ahmed R; Sowden MP; Doyley MM; Berk BC
    Br J Pharmacol; 2019 Aug; 176(15):2795-2807. PubMed ID: 31077344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.